União Europeia - português - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/6/2021(h3n2)-like strain (a/darwin/11/2021, wild type) / a/wisconsin/67/2022 (h1n1)pdm09-like strain (a/georgia/12/2022 cvr-167) / b/austria/1359417/2021-like strain (b/singapore/wuh4618/2021) / b/phuket/3073/2013-like virus (b/singapore/inftt-16-0610/2016, wild type) - influenza humana - influenza, inativada, de divisão de vírus ou antígeno de superfície do - prophylaxis of influenza in adults and children from 2 years of age. flucelvax tetra deve ser utilizado em conformidade com as recomendações oficiais.

União Europeia - português - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - parvovírus suíno, tensão 27a, proteína viral 2 - imunológicos para suidae - porcos - para a imunização ativa de leitoas e porcas a partir da idade de 5 meses para proteger a prole contra transplacentária da infecção causada pelo parvovírus suíno.

União Europeia - português - EMA (European Medicines Agency)

laboratorios hipra s.a. - vivo atenuado bovina vírus sincicial respiratório (brsv), tensão lym-56 - imunológicos para bovidae, gado, ao vivo viral vacinas, bovinos vírus sincicial respiratório (brsv) - gado - imunização ativa de gado para reduzir o derramamento de vírus respiratórios e sinais clínicos causados por bovinos vírus sincicial respiratório infecção.

União Europeia - português - EMA (European Medicines Agency)

laboratorios hipra, s.a. - vivo atenuado infecciosas radiação do vírus da doença (ibdv), tensão 1052 - imunológicos para aves, aves domésticas, ao vivo viral vacinas, infecciosa aviária radiação do vírus da doença (doença de gumboro) - chicken; embryonated chicken eggs - para a imunização ativa de 1 dia de idade de frangos de corte filhotes e embryonated de frangos de corte ovos de galinha para reduzir os sinais clínicos e lesões da bursa de fabricius causadas por muito virulenta aviária infecciosas radiação doença de infecção pelo vírus.

União Europeia - português - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - frango - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

União Europeia - português - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacinas - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. o uso desta vacina deve ser de acordo com as recomendações oficiais.

União Europeia - português - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - porcos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

União Europeia - português - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - frango - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

União Europeia - português - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infecções respiratórias do vírus sincitial - vacinas - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. veja as seções 4. 2 e 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. o uso desta vacina deve ser de acordo com as recomendações oficiais.

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

aj vaccines a/s - vacina contra a poliomielite - solução injetável em seringa pré-cheia - associação - vírus da poliomielite inactivado, tipo 1 80 u/ml ; vírus da poliomielite inactivado, tipo 3 64 u/ml ; vírus da poliomielite inactivado, tipo 2 16 u/ml - poliomyelitis, trivalent, inactivated, whole virus - n/a - duração do tratamento: curta ou média duração